Skip to main content
Clinical Trials/NCT03107455
NCT03107455
Completed
Not Applicable

European Registry of MitraClip in Acute Myocardial Infarction

Fundación Investigación Sanitaria en León0 sites50 target enrollmentJanuary 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mitral Regurgitation
Sponsor
Fundación Investigación Sanitaria en León
Enrollment
50
Primary Endpoint
Composite primary end point
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Acute MR may develop in the setting of an acute myocardial infarction (AMI) as a result of papillary muscle dysfunction or rupture, and these patients are grossly underrepresented in MitraClip registries. Our group has recently published the Spanish experience with MitraClip in acute MI, but only 5 patients could be collected. However, the results of our initial experience are highly encouraging since patients performed well in such life-threatening condition. In order to expand the information of the device in this condition, our aim is to start a multinational registry in Europe.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
December 1, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Fundación Investigación Sanitaria en León
Responsible Party
Principal Investigator
Principal Investigator

Felipe Fernandez Vazquez

MD PhD

Fundación Investigación Sanitaria en León

Eligibility Criteria

Inclusion Criteria

  • Patient ≥ 18 year-old
  • Transmural myocardial infarction in the previous 4 weeks (managed under current guideline's recommendations).
  • Symptomatic severe mitral regurgitation diagnosed by left ventriculography, transthoracic echo or trans-oesophageal echo. Symptoms may vary form heart failure to cardiogenic shock.
  • Symptoms should be stabilized by medical management: iv diuretics, inotropic support, LV assistance devices
  • Considered by heart team at high risk for conventional surgery

Exclusion Criteria

  • Anatomy not suitable for MitraClip implantation
  • Technical contraindication for access to left atrium
  • Patient candidate for emergent heart transplant
  • Uncontrolled infection

Outcomes

Primary Outcomes

Composite primary end point

Time Frame: 6 month

death from cardiac causes, readmission due to heart failure and mitral regurgitation \>2+

Similar Trials